Copy number variation of the Beta-defensin genes in europeans: no supporting evidence for association with lung function, chronic obstructive pulmonary disease or asthma by Wain, Louise V. et al.
Copy Number Variation of the Beta-Defensin Genes in
Europeans: No Supporting Evidence for Association with
Lung Function, Chronic Obstructive Pulmonary Disease
or Asthma
Louise V. Wain1*, Linda Odenthal-Hesse2, Razan Abujaber2, Ian Sayers3, Caroline Beardsmore4,5,
Erol A. Gaillard4,5, Sally Chappell6, Cristian M. Dogaru7, Tricia McKeever8, Tamar Guetta-Baranes6,
Noor Kalsheker6, Claudia E. Kuehni7, Ian P. Hall3, Martin D. Tobin1,2,5, Edward J. Hollox2
1Department of Health Sciences, University of Leicester, Leicester, United Kingdom, 2Department of Genetics, University of Leicester, Leicester, United Kingdom,
3Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 4Department of Infection, Immunity and Inflammation,
University of Leicester, Leicester, United Kingdom, 5 Institute for Lung Health, National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit,
Glenfield Hospital, Leicester, United Kingdom, 6 School of Life Sciences, University of Nottingham, Nottingham, United Kingdom, 7 Institute of Social and Preventive
Medicine, University of Bern, Bern, Switzerland, 8 School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom
Abstract
Lung function measures are heritable, predict mortality and are relevant in diagnosis of chronic obstructive pulmonary
disease (COPD). COPD and asthma are diseases of the airways with major public health impacts and each have a heritable
component. Genome-wide association studies of SNPs have revealed novel genetic associations with both diseases but only
account for a small proportion of the heritability. Complex copy number variation may account for some of the missing
heritability. A well-characterised genomic region of complex copy number variation contains beta-defensin genes (DEFB103,
DEFB104 and DEFB4), which have a role in the innate immune response. Previous studies have implicated these and related
genes as being associated with asthma or COPD. We hypothesised that copy number variation of these genes may play a
role in lung function in the general population and in COPD and asthma risk. We undertook copy number typing of this
locus in 1149 adult and 689 children using a paralogue ratio test and investigated association with COPD, asthma and lung
function. Replication of findings was assessed in a larger independent sample of COPD cases and smoking controls. We
found evidence for an association of beta-defensin copy number with COPD in the adult cohort (OR= 1.4, 95%CI:1.02–1.92,
P = 0.039) but this finding, and findings from a previous study, were not replicated in a larger follow-up sample(OR= 0.89,
95%CI:0.72–1.07, P = 0.217). No robust evidence of association with asthma in children was observed. We found no evidence
for association between beta-defensin copy number and lung function in the general populations. Our findings suggest
that previous reports of association of beta-defensin copy number with COPD should be viewed with caution. Suboptimal
measurement of copy number can lead to spurious associations. Further beta-defensin copy number measurement in larger
sample sizes of COPD cases and children with asthma are needed.
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Introduction
Lung function measures are heritable traits that predict
morbidity and mortality in the general population [1–4]. The
ratio of forced expired volume in 1 second (FEV1) to forced vital
capacity (FVC) is used in diagnostic criteria for Chronic
obstructive pulmonary disease (COPD), whilst the FEV1 (ex-
pressed as % predicted FEV1) contributes to measures of COPD
severity. Genome-wide association studies (GWAS) of single
nucleotide polymorphisms (SNPs) have identified 26 regions of
the genome showing association with FEV1 and/or FEV1/FVC
[5–7]. Collectively these 26 variants only account for approxi-
mately 3.2% of the additive polygenic variance in FEV1/FVC [7].
COPD, characterised by irreversible airway obstruction, is a
leading cause of global mortality and morbidity predicted to be the
third leading cause of death by 2020 [8]. Although the major risk
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factor for COPD is smoking, there is a heritable component [9].
We previously hypothesised that some the genetic determinants of
lung function would be genetic causes of COPD. Of the 26
genomic regions associated with lung function, 8 have so far been
reported to be associated with airway obstruction or COPD [10–
14].
Asthma, a form of reversible airway obstruction, has increased
in prevalence and more than 300 million people worldwide are
affected [15]. Whilst GWAS for asthma have shown association
with at least 10 genomic regions, including those encoding proteins
involved in the immune response [16–19], these variants explain
only around 4% of asthma heritability [20]. Thus, most of the
genetic determinants of lung function, COPD and asthma are yet
to be identified. Copy number variation (CNV) is a type of genetic
variation where sections of the genome are duplicated or deleted.
It is currently estimated that up to 4% of the genome may be copy
number variable [21]. Copy number variation, particularly
complex copy number variation which is poorly tagged by the
variants commonly studied in GWAS, may explain some of the
remaining unexplained heritability of these clinically important
traits.
One of the best-characterised regions of complex copy number
variation is the beta-defensin locus; the repeat unit (referred to
hereafter as DEFB) contains several beta defensin genes;
DEFB107, DEFB106, DEFB105, DEFB104, DEFB103 and DEFB4
and also SPAG11, which vary in copy number as a block. In
addition to their direct antimicrobial function, these beta-defensins
can act as chemokines having an immunomodulatory role (for
review see [22]). Both DEFB4 and DEFB103 are expressed in the
lung and trachea [23,24], and the mature peptides hbd2 (encoded
by the gene DEFB4) and hbd3 (encoded by the gene DEFB103)
have antimicrobial activity against a range of pathogens that are
known to infect the airway [25]. The mature peptide hbd4
(encoded by the gene DEFB104) is also present in appreciable
quantities in the lung [26], and expression of these three beta-
defensins are modulated by pro-inflammatory molecules or
bacteria [27,28]. In the UK population, DEFB copy numbers of
between 2 and 10 are observed at an appreciable frequency
[29,30]. Thus there has been considerable interest in relating
DEFB copy number to immune-related diseases including COPD
and asthma, as well as psoriasis [31,32]. However, the findings
from association studies of other diseases have not always been
consistent and replicable [33–36].
We determined DEFB diploid copy number using a Paralogue
Ratio Test (PRT), a method shown to have higher accuracy than
previously employed methods [29], in a total of 2343 individuals
from two UK-based general population cohorts of adults and
children (Table 1 and Table 2). We tested association firstly with
quantitative measures of lung function in all individuals (FEV1,
FVC and FEV1/FVC) and with risk of asthma and risk of COPD
in subsets of each cohort.
Materials and Methods
Ethics Statement
The Gedling study was approved by the Nottingham City
Hospital and Nottingham University Ethics committees (MREC/
99/4/01) and written informed consent for genetic study was
obtained from participants. The Leicester Respiratory Cohort was
approved by the Leicestershire Health Authority Research Ethics
Committee, Leicester, UK (07/H0407/70) and written informed
consent for genetic study was obtained from the subjects and their
parents. For the replication COPD cases and controls, approval
was obtained from Southmead Local Research Ethics Committee,
Bristol (134/01), and Lothian Research Ethics Committee,
Edinburgh (LREC/2001/4/62) and written informed consent
for genetic study was obtained from participants.
Sample selection
Gedling. The Gedling cohort is a general population sample
recruited in Nottingham in 1991 (18 to 70 years of age, n= 2,633)
[37] and then followed-up in 2000 (n= 1346) when blood samples
were taken for DNA extraction and FEV1 and FVC were
measured using a calibrated dry bellows spirometer (Vitalograph,
Buckingham, UK), recording the best of three satisfactory attempts
[38]. DNA was extracted by Source Biosciences, UK. A total of
1176 European ancestry individuals for whom DNA and non-
missing relevant phenotype data (age, sex, height, FEV1 (pre-
bronchodilator), FVC (pre-bronchodilator), smoking status, asth-
ma diagnosis) were available and were typed for DEFB copy
number using PRT. Doctor diagnosed asthma cases in Gedling
were defined as individuals for whom an asthma diagnosis had
been confirmed by a doctor [37] (however, individuals with %
predicted FEV1,80% and FEV1/FVC,0.7 (COPD GOLD stage
2 [39]) were excluded from both doctor diagnosed asthma case
and control sets. Percent predicted FEV1 was calculated according
to previously described equations [40,41]). COPD cases were
defined in Gedling as individuals age.40, smoking pack years.5,
% predicted FEV1,80% and FEV1/FVC,0.7 (COPD GOLD
stage 2 and above [39]). Controls for the COPD analysis were
defined as age.40, pack years .5, %predicted FEV1.80% and
FEV1/FVC.0.7. Individuals with a doctor diagnosis of asthma
were excluded from the COPD case and control sets. Character-
istics of these samples are given in Table 1 and Table 2. Figure 1
(top) illustrates how samples were selected for each analysis.
Leicester Respiratory Cohort (LRC). The paediatric
dataset comes from a population-based respiratory cohort in
Leicestershire, UK, described in detail elsewhere [42]. In short,
perinatal data were collected at birth, and data on growth and
development were acquired prospectively during childhood.
Respiratory morbidity and individual and family-related exposures
were assessed by repeated questionnaires (1998, 2001, 2003, 2006,
2010). In 2006 to 2010, families who had returned two or more
questionnaires (n = 4,125) were invited to the laboratory for
assessment of lung function by spirometry [43,44]. We recorded
FVC and FEV1 before and 15 minutes after administration of
Table 1. Characteristics of Gedling and LRC individuals
included in the study.
LRC (n =689) Gedling (n =1149)
Age (mean[range]) 12.8 [7.8–14.2] 56.1 [27.5–80.1]
Sex (males:females) 354:335 569:580
Height cm (mean[range]) 156.4 [122.6–187.7] 168.0 [145.0–204.0]
FEV1 litres (mean[range]) 2.70 [1.17–4.71] 2.86 [0.51–5.81]
FVC litres (mean[range]) 3.08 [1.43–5.84] 3.68 [0.80–7.13]
FEV1/FVC (mean[range]) 0.88 [0.64–0.997] 0.77 [0.35–0.96]
Doctor diagnosed asthma
(yes:no)
255:434 45:629*
Asthma-ICS 82:441 na
COPD GOLD Stage 2 na 42:189#
*Individuals with % predicted FEV1,80% and FEV1/FVC,0.7 (GOLD stage 2
cases) excluded from cases and controls. #Characteristics of cases and controls
are shown in Table 2.
doi:10.1371/journal.pone.0084192.t001
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salbutamol (400 mg) by spacer. Pre-bronchodilator measurements
were used in this study. Of 4,177 children who attended the lab,
903 individuals had saliva samples available for DNA extraction.
DNA was extracted by LGC Genomics Ltd (previously KBios-
ciences Ltd). Of these, 689 were of European ancestry (self-
reported), aged under 16 years and had non-missing relevant
phenotype data (age, sex, height, FEV1, FVC, and asthma
variables). The LRC is an unselected population-based cohort
and most children reporting a doctor diagnosis of asthma had mild
disease. Therefore, a potentially more clinically relevant subpop-
ulation with moderately severe asthma was also defined as
individuals who had ever reported frequent wheeze during the
past 12 months (over four attacks or always accompanied by
shortness of breath) and were taking inhaled corticosteroids at the
time of questionnaire (controls for this analysis were all individuals
who had never reported frequent wheeze during the past 12
months, were not taking inhaled corticosteroids at the time of
questionnaire and did not report a doctor diagnosis of asthma).
This phenotype is referred to hereafter as ‘‘asthma-ICS’’.
Characteristics of LRC subjects are given in Table 1. Figure 1
(bottom) illustrates how samples were selected for each analysis.
COPD replication collection. The criteria for recruitment
of cases and controls in the replication collection are described
elsewhere [45]. In brief, the criteria for cases was % predicted
FEV1,=70%, FEV1/FVC,70%, no significant reversibility on
bronchodilation, a smoking history of .=20 pack years, and no
diagnosis of asthma or other alternative diagnosis for airway
obstruction (including severe SERPINA1 deficiency). Controls
were selected who had no history of airway obstruction or recent
pulmonary infection, and had % predicted FEV1.=80% and
FEV1/FVC.70% and were selected to match the cases for age
and sex. Controls were current or ex-smokers with smoking history
similar to that of the cases. A total of 251 UK cases (112 from
Bristol and 139 from Edinburgh) and 227 UK controls (136 from
Bristol and 91 from Edinburgh) were copy number genotyped for
DEFB copy number using PRT in the same laboratory as the
Gedling and LRC samples. Cases and controls were randomised
and the individual undertaking the assays was blind to COPD
status. All individuals were of European ancestry. Characteristics
of these samples are given in Table 2.
DEFB copy number assay
The DEFB copy number was determined, blind to clinical
information, using a triplex PRT described previously [29,46].
Every experiment included the same six positive controls of known
copy number, the same samples as used in previous studies
[29,30], which were used to normalize the experimental results
and minimize interexperimental technical variation in typing copy
number. Maximum likelihood integer copy number was called by
combining information from all three assays and estimating the
most likely copy number given the data. In addition, non-integer
copy number values were calculated by averaging the estimates
from the three assays.
Statistical analysis
Association of the average raw PRT DEFB copy numbers with
lung function in all individuals (FEV1, FVC and FEV1/FVC),
COPD status (Gedling only) and asthma status (doctor diagnosed
asthma in both cohorts and asthma-ICS in LRC) was tested using
linear and logistic regression. Association of the maximum
likelihood integer copy numbers with lung function, COPD status
and asthma status was also undertaken. Age, age2, sex and height
were included as covariates. Inverse normal transformation was
applied to FEV1 and FEV1/FVC. R v2.15.2 was used to run all
association analyses. Power was estimated by a simulated study of
equivalent size to the Gedling study (n= 1149) with a similar
distribution of DEFB copy number to that observed in our data.
At a significance level of 0.05, power was 95% to detect an effect
size of 0.1 SD change in lung function per one unit change in
DEFB copy number. In 42 COPD cases and 189 controls,
simulations showed, for a significance level of 0.05, power of 88%
to detect an OR of 1.7 per unit change in DEFB copy number.
Power simulations were run using Stata version 13.
Replication analysis
A subset of a larger European ancestry COPD case-control
study was used to test for replication of an association with COPD
observed in the Gedling cohort. Logistic regression was used to test
for association with COPD using age, age2, sex and height as
covariates in the model. Comparison of distributions of copy
numbers was undertaken using a Mann-Whitney-Wilcoxon test
and comparison of frequencies of samples with copy number
.=5 in cases and controls was undertaken using a Pearson’s chi-
squared test (undertaken using R v2.15.2).
Results
DEFB copy number was successfully measured using PRT in
689 LRC children and 1149 Gedling adults (Table 1). The
distributions of raw PRT copy numbers and maximum likelihood
integer copy numbers for each cohort are shown in Figure 2. In
LRC, maximum likelihood integer copy numbers ranged from 1
Table 2. Characteristics of Gedling and replication COPD cases and controls.
Gedling Replication
Cases (n =42) Controls (n =189) Cases (n =251) Controls (n =227)
Age (mean[range]) 67.4[45–80] 59.4[41–80] 66.8[35–90] 57.0[38–88]
Sex (Males:Females) 31:11 119:70 142:109 95:132
Height (mean[range]) 168.3[145–182] 168.8[146–190] 166.1[148–188] 167.1[146–190]
FEV1 (mean[range]) 1.72[0.7–2.93] 2.97[1.65–5.14] 1.01[0.25–2.53] 2.80[1.38–4.83]]
% predicted FEV1 (mean[range]) 60.9[24.0–79.9] 97.3[80.2–151.7] 37.8[11.2–77.2] 93.5[80.0–127.7]
FVC (mean[range]) 2.79[1.36–4.32] 3.78[2.15–9.65] 2.20[0.82–4.17] 3.52[1.64–6.61]
FEV1/FVC (mean[range]) 0.61[0.35–0.70] 0.79[0.70–0.92] 0.46[0.13–0.69] 0.79[0.71–0.97]
Smoking pack years (mean[range]) 42.7[6–150] 22.5[5–90] 46.6[20–150] 35.6[20–145]
doi:10.1371/journal.pone.0084192.t002
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to 9 with a mean copy number of 4.06. In the Gedling population,
copy numbers ranged from 1 to 9 with a mean of 4.3. Association
of DEFB raw PRT copy number and lung function (FEV1, FVC
and FEV1/FVC), COPD (Gedling only) and asthma was tested
separately in each cohort and the results are presented in Table 3.
Association of maximum likelihood integer copy numbers of
DEFB with all traits were also undertaken and the results were
consistent with those obtained using the raw PRT copy numbers
(results not shown).
Although there was no evidence for association of DEFB copy
number with lung function in all individuals in either cohort (even
when the data for adults were stratified by smoking status), a
significant (P,0.05) signal of association of DEFB copy number
with COPD was observed within the adult Gedling population
(OR=1.34, 95% CI:1.02–1.77, P= 0.039) (Figure 3). When we
sought replication in a sample of 251 UK COPD cases and 227
UK controls [45], there was no evidence for association of DEFB
copy number and COPD (OR=0.89, 95% CI:0.72–1.07,
P = 0.217) (Figure 3). In fact, we found a trend for an association
in the opposite direction (increased copy number associated with
decreased risk of COPD) to that observed in the Gedling
population.
We did not observe evidence for association of DEFB copy
number with doctor-diagnosed asthma for either LRC or Gedling.
Because the majority of the children with doctor-diagnosed
asthma in LRC had very mild disease, we also used a stricter
definition of clinically relevant asthma (asthma-ICS) in LRC. We
found a significant association of DEFB copy number with
asthma-ICS for LRC (OR=1.26, 95% CI:1.07–1.54, P = 0.016).
However, a comparison of the distributions of DEFB copy number
in the asthma-ICS cases and controls showed that the signal was
driven by 2 cases with high copy numbers (Figure 4). After
exclusion of these two individuals the strength of the association
decreased considerably (OR=1.18, 95% CI: 0.96–1.44, P = 0.12).
Discussion
This study determined DEFB diploid copy number in a cohort
of 1149 adults and in a separate cohort of 689 children using PRT,
which is currently the most accurate method for measuring copy
number variation at this locus. The distributions of copy number
observed in each cohort were in good agreement with previously
published distributions from the UK population [29,47], although
in the LRC cohort we observed nine children (.1%) with a copy
Figure 1. Sample selection for association analyses in Gedling and LRC. The sampling frame for each cohort is shown centrally with the
COPD and asthma association analysis sample subsets indicated above and below for each cohort.
doi:10.1371/journal.pone.0084192.g001
Figure 2. Distributions of raw PRT copy number (top) and maximum likelihod integer copy number (bottom) for Gedling (right) and
LRC (left) cohorts.
doi:10.1371/journal.pone.0084192.g002
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number of 1, which in other cohorts is rare. We tested for
association with lung function as a quantitative measurement
(FEV1 and FEV1/FVC) in all individuals in each cohort as well as
for association with COPD and asthma using appropriate case
and control subsets of individuals within each cohort. Previous
studies have reported some evidence for association of other
beta-defensins with COPD [48,49] and asthma [50]. However,
our study, using a reliable measure of DEFB (comprising DEFB4,
DEFB103 and DEFB104 genes) copy number, does not show a
strong effect of DEFB copy number on these traits. In addition, we
found no evidence for association with lung function in the general
population.
Table 3. Association of DEFB with lung function, asthma and COPD in LRC and Gedling.
LRC Gedling
Lung function
(inverse normal transformed)
N Beta SE P N Beta SE P
FEV1 689 0.019 0.020 0.333 1149 20.026 0.016 0.114
FVC 689 0.014 0.020 0.490 1149 20.008 0.015 0.581
FEV1/FVC 689 0.019 0.030 0.525 1149 20.043 0.025 0.090
FEV1/FVC - never smokers only 647 20.036 0.031 0.252
FEV1/FVC - ever smokers only 502 20.067 0.0417 0.106
Asthma N
(case:control)#
OR CI P N
(case:control)#
OR CI P
Doctor diagnosed asthma 255:434 1.08 0.95–1.23 0.244 45:629 1.03 0.79–1.37 0.784
Asthma-ICS 82:441 1.26 1.07–1.54 0.016*
COPD N
(case:control)#
OR CI P
COPD GOLD Stage 2 42:189 1.40 1.02–1.92 0.039
*P = 0.043 if maximum likelihood DEFB integer copy numbers used #controls for each analysis as defined in the method.
doi:10.1371/journal.pone.0084192.t003
Figure 3. Cumulative frequency distribution of average raw PRT DEFB copy number in Gedling COPD cases and controls (left) and
replication COPD cases and controls (right).
doi:10.1371/journal.pone.0084192.g003
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A previous study presented evidence of an association of higher
DEFB copy number with increased expression levels in nasal
epithelial cells and with a higher risk of COPD [51]. Janssens et al
[51] used real time quantitative PCR to measure diploid DEFB
copy number and test for association with COPD in 204 COPD
cases and 154 healthy smoker controls. A significant association
was observed with the cases having a significantly higher median
copy number than the controls (median of 5 in cases, 4 in controls,
P,0.0001). In our replication collection of 251 cases and 227
controls, the median copy number was not significantly different in
cases and controls (median of 4.05 in cases, 4.12 in controls,
P = 0.316). Janssens et al showed a significant difference in the
proportion of individuals with a copy number .=5 in the COPD
cases compared to the control group (52% and 38%, respectively,
P = 0.008). However, in our replication collection, an opposite
effect was seen with 18% of cases having copy number .=5 and
20% of controls having copy number .=5 (P= 0.67). We found
no significant association between high copy number (.=5
copies) and COPD risk (OR=0.88, 95% CI: 0.6–1.4).
We recognise that the small case and control sample subsets
within the Gedling cohort would limit statistical power to detect
association with COPD risk and that diagnosis of COPD in this
cohort was not based on reversibility. Previous genome-wide
significant SNP associations with COPD have given ORs in the
order of 1.1 to 1.3 per copy of the risk allele [10,13]. In our
discovery sample set (42 cases and 189 controls) we would have
had 88% power to detect an OR of 1.7 per unit change in DEFB4
copy number. Power would have been higher in the larger
replication set. However, we were not able to replicate the findings
of Janssens et al [51]. Non-replication of the COPD association
identified in the Gedling cohort by our replication collection may
have been due to differences in the distributions of lung function
measures between the discovery and replication case collections.
This may be explained by differences in the ascertainment strategy
of cases in each collection (diagnosis was based on reversibility in
the replication collection). Given that SNPs reported in genome-
wide association studies as associated with COPD also show
association with lung function in general population samples [10–
14] one might have expected any CNV showing association with
COPD to be associated with lung function. Genome-wide
significant associations with effect sizes of 0.03 to 0.09 standard
deviations from the mean per allele have been observed for GWAS
of SNPs including tens of thousands of samples [6,7]. We had 75%
power to detect an effect size of 0.075 per one unit change in
DEFB4 copy number in the Gedling cohort (n = 1149).
A significant signal of association of DEFB copy number with a
clinically relevant definition of asthma (asthma-ICS) in LRC was
found to be driven by two cases with high copy number. The raw
results from each independent component of the triplex PRT assay
(data not shown) were consistent suggesting that the high copy
numbers were real for these two cases. Although exclusion of these
two individuals weakened the signal, we cannot rule out that rare
instances of very high copy number could be causative for asthma.
LRC recruitment included children of European and South
Asian ancestry; we limited this study to individuals of European
ancestry based on questionnaire data (for ease of comparison with
Gedling). Although there are no large differences in DEFB copy
number variation across the world, some subpopulations, includ-
ing two from South Asia, have been found to have outlying
distributions of DEFB copy number [30].
The high mutation rate and multiallelic nature of the DEFB
copy number variation means it is poorly tagged by nearby SNP
alleles and measurement based on SNP probe intensity data is
inadequate [30,52,53]. In this study, we measured DEFB copy
number using PRT which has been shown to have higher
accuracy for calling copy number than real time qPCR [46]. PRT
is a form of qPCR which can more reliably measure copy number,
particularly higher diploid copy numbers, through the use of
identical primers to target the copy number variable region and a
two-copy reference region. This avoids the issue of differential
primer binding which can be a feature of real-time qPCR copy
number measurement. Inaccurate copy number measurement has
resulted in erroneous association of copy number with disease
from this and other complex copy number variable regions. The
previously reported association of DEFB copy number with
COPD, described in detail above and not replicated in this study,
was based on real-time qPCR measurements [51].
In conclusion, this study does not support previous findings of
an association of DEFB copy number variation with COPD. We
suggest that previous associations may have been due to inaccurate
copy number measurement. A strength of our study was the
accurate method of measurement of copy number. Prior to 2008,
candidate SNP-based association studies often reported inconsis-
tent findings, however these problems have diminished with the
very large sample sizes now commonly employed in genome-wide
association studies. Accurate copy number typing of very large
studies will be needed to confidently rule out any modest effect of
DEFB copy number variation on lung function, COPD or asthma.
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